who manufactures glp-1 drugs Market Overview: Agonists and the Obesity Market | Blog Medicare GLP-1 Drug Coverage -

There may be reduced risk in microdosing GLP-1s, especially if youre doing it under the care of a healthcare provider (as you should)

[DOI] [PMC free article] [PubMed] [Google Scholar] 93.Tsapas A, Karagiannis T, Kakotrichi P, Avgerinos I, Mantsiou C, Tousinas G, et al

Consequently, suppression of IL-1 via GLP-1 receptor mediation, particularly through the pathway involving PKC-mediated inhibition of the nucleotide-binding domain, leucine-rich-containing family, pyrin-domain-containing-3 (NLRP3) inflammasome, can further contribute to reducing the formation of a profibrotic environment

doi: 10.1111/dom.14947 [DOI] [PubMed] [Google Scholar] 15

Monitoring thyroid function every three to six months during active GLP-1 therapy, and specifically requesting free T3 along with TSH and free T4, helps catch these shifts early